JP2024054410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024054410A5 JP2024054410A5 JP2024028737A JP2024028737A JP2024054410A5 JP 2024054410 A5 JP2024054410 A5 JP 2024054410A5 JP 2024028737 A JP2024028737 A JP 2024028737A JP 2024028737 A JP2024028737 A JP 2024028737A JP 2024054410 A5 JP2024054410 A5 JP 2024054410A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- igf11
- derived
- light chain
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096344 | 2020-06-02 | ||
| JP2020096344 | 2020-06-02 | ||
| PCT/JP2021/020890 WO2021246413A1 (ja) | 2020-06-02 | 2021-06-01 | 抗ｉｇｆ－１受容体ヒト化抗体 |
| JP2022528850A JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528850A Division JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024054410A JP2024054410A (ja) | 2024-04-16 |
| JP2024054410A5 true JP2024054410A5 (https=) | 2024-06-10 |
Family
ID=78831168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528850A Pending JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 | |
| JP2024028737A Pending JP2024054410A (ja) | 2020-06-02 | 2024-02-28 | 抗ｉｇｆ－１受容体ヒト化抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528850A Pending JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250263489A1 (https=) |
| EP (1) | EP4159860A4 (https=) |
| JP (2) | JPWO2021246413A1 (https=) |
| KR (1) | KR20230006006A (https=) |
| CN (1) | CN115605594A (https=) |
| AR (1) | AR122499A1 (https=) |
| AU (1) | AU2021282629A1 (https=) |
| BR (1) | BR112022022030A2 (https=) |
| CA (1) | CA3176119A1 (https=) |
| CL (1) | CL2022003399A1 (https=) |
| CO (1) | CO2022017026A2 (https=) |
| IL (1) | IL296519A (https=) |
| MX (1) | MX2022015133A (https=) |
| TW (1) | TW202210513A (https=) |
| WO (1) | WO2021246413A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230357384A1 (en) * | 2020-06-18 | 2023-11-09 | Nextcure, Inc. | Compositions and methods for modulating flrt3 mediated signal transduction |
| CN114561337B (zh) * | 2022-03-09 | 2023-10-03 | 广州源井生物科技有限公司 | 一种提高HepG2细胞克隆形成率的单克隆增强培养基和方法 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| AU2013251312B2 (en) * | 2012-04-27 | 2018-03-22 | Takeda Pharmaceutical Company Limited | Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| AR112600A1 (es) * | 2017-05-30 | 2019-11-20 | Teijin Pharma Ltd | Anticuerpo anti-receptor de igf-i |
| WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| JP2021513367A (ja) * | 2018-02-12 | 2021-05-27 | ダイアベーツ−フリー， インコーポレイテッド | 改善されたアンタゴニスト的抗ヒトｃｄ４０モノクローナル抗体 |
| GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| BR112021010479A2 (pt) * | 2018-12-03 | 2021-11-16 | Teijin Pharma Ltd | Anticorpo humanizado anti-receptor de igf-i ou fragmento ou derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo para produção de um anticorpo humanizado anti-receptor de igf-i ou fragmento ou derivado do mesmo, e, composição farmacêutica |
-
2021
- 2021-06-01 CN CN202180039577.1A patent/CN115605594A/zh active Pending
- 2021-06-01 IL IL296519A patent/IL296519A/en unknown
- 2021-06-01 BR BR112022022030A patent/BR112022022030A2/pt unknown
- 2021-06-01 MX MX2022015133A patent/MX2022015133A/es unknown
- 2021-06-01 KR KR1020227042511A patent/KR20230006006A/ko active Pending
- 2021-06-01 JP JP2022528850A patent/JPWO2021246413A1/ja active Pending
- 2021-06-01 US US18/007,606 patent/US20250263489A1/en active Pending
- 2021-06-01 TW TW110119805A patent/TW202210513A/zh unknown
- 2021-06-01 EP EP21817253.4A patent/EP4159860A4/en active Pending
- 2021-06-01 AR ARP210101492A patent/AR122499A1/es unknown
- 2021-06-01 WO PCT/JP2021/020890 patent/WO2021246413A1/ja not_active Ceased
- 2021-06-01 CA CA3176119A patent/CA3176119A1/en active Pending
- 2021-06-01 AU AU2021282629A patent/AU2021282629A1/en active Pending
-
2022
- 2022-11-28 CO CONC2022/0017026A patent/CO2022017026A2/es unknown
- 2022-12-01 CL CL2022003399A patent/CL2022003399A1/es unknown
-
2024
- 2024-02-28 JP JP2024028737A patent/JP2024054410A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024054410A5 (https=) | ||
| JP2021105034A5 (https=) | ||
| MX2022015133A (es) | Anticuerpo humanizado anti-receptor de igf-1. | |
| CY1124289T1 (el) | Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7 | |
| JP2022031635A5 (https=) | ||
| JP2019122405A5 (https=) | ||
| JP2019054802A5 (https=) | ||
| RU2014142680A (ru) | Способ улучшения функциональных свойств антитела или его антигенсвязывающего фрагмента | |
| JP2016513682A5 (https=) | ||
| BR0318454A (pt) | anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos | |
| JP2011173884A5 (https=) | ||
| JP2024156657A5 (https=) | ||
| EP2796466A3 (en) | Humanized antibody molecules specific for IL-31 | |
| PE20061152A1 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloideo | |
| DE602005022928D1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
| JP2016516400A5 (https=) | ||
| JP2012176953A5 (https=) | ||
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| JP2010536384A5 (https=) | ||
| JP2003528052A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2019506412A5 (https=) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav |